Estravac 2 Tablet

Estravac 2 Tablet is a hormone replacement therapy (HRT) medication containing Estradiol (2 mg), a form of estrogen hormone. Below is a detailed product description based on available information about estradiol 2 mg tablets, as specific details for "Estravac" are not widely documented in the provided references. The description is derived from general information about estradiol tablets, such as those marketed under brand names like Estrace or Estrabet, which are similar in composition.

Product Description: Estravac 2 Tablet (Estradiol 2 mg)

Composition:

• Active Ingredient: Estradiol (micronized), 2 mg per tablet.
• Inactive Ingredients: May include colloidal silicon dioxide, corn starch, dibasic calcium phosphate, lactose monohydrate, magnesium stearate, sodium starch glycolate, and FD&C Yellow No. 5 (tartrazine) and FD&C Blue No. 1 aluminum lake (common in estradiol 2 mg tablets). Note: FD&C Yellow No. 5 may cause allergic reactions, including bronchial asthma, in susceptible individuals, particularly those with aspirin hypersensitivity.

Pharmacological Class: Estrogen hormone (17β-estradiol), a naturally occurring steroid hormone responsible for the development and maintenance of the female reproductive system and secondary sexual characteristics. Estradiol is the most potent human estrogen, more effective than its metabolites (estrone and estriol) at estrogen receptor levels.

Indications: Estravac 2 Tablet is primarily used for:

1. Menopausal Symptoms: Relieves moderate to severe vasomotor symptoms (e.g., hot flashes, night sweats) and symptoms of vulvar/vaginal atrophy (e.g., dryness, burning, itching) associated with menopause.
2. Osteoporosis Prevention: Helps prevent postmenopausal osteoporosis by reducing bone mass loss in women at high risk of fractures. Note: It does not restore bone mass to premenopausal levels.
3. Hypoestrogenism: Treats low estrogen levels due to hypogonadism, castration, or primary ovarian failure.
4. Cancer Treatment: Used for palliation in selected cases of metastatic breast cancer (in women and men) and advanced androgen-dependent prostate cancer.

Mechanism of Action: Estradiol replaces the natural estrogen hormone in the body, maintaining adequate levels of circulating hormones. It binds to estrogen receptors (ERα and ERβ) in various tissues, including the reproductive system, bones, and brain, to:

• Alleviate menopausal symptoms by improving vaginal health and regulating body temperature.
• Reduce bone resorption to prevent osteoporosis.
• Inhibit androgen production in hormone-sensitive cancers (e.g., prostate cancer) by suppressing gonadal sex hormone production.

Dosage and Administration:

• Menopausal Symptoms and Hypoestrogenism: Typical starting dose is 1–2 mg daily, taken orally, adjusted based on symptom control. Administration is often cyclic (e.g., 3 weeks on, 1 week off) to minimize risks. The minimal effective dose should be determined by titration.
• Osteoporosis Prevention: The lowest effective dose is used, tailored to individual risk and response.
• Breast/Prostate Cancer: Higher dose of 10 mg three times daily for at least 3 months.
• Instructions: Swallow the tablet with water, with or without food, at the same time daily for consistency. If a dose is missed by less than 12 hours, take it as soon as remembered; if more than 12 hours, skip the missed dose and resume the regular schedule. Do not double the dose.

Contraindications: Do not use Estravac 2 Tablet if you have:

• Known hypersensitivity to estradiol or any ingredients (e.g., tartrazine).
• Undiagnosed abnormal vaginal bleeding.
• Known, suspected, or history of breast cancer (except for palliation in selected cases).
• Estrogen-dependent cancers (e.g., endometrial, ovarian).
• Active or recent history of deep vein thrombosis (DVT), pulmonary embolism (PE), or arterial thromboembolic disease (e.g., stroke, myocardial infarction).
• Liver dysfunction or disease.
• Known or suspected pregnancy (no indication in pregnancy).

Side Effects:

• Common: Breast tenderness, headache, nausea, vomiting, abdominal pain, bloating, vaginal discharge, weight changes, mood alterations (e.g., anxiety, depression).
• Serious: Increased risk of endometrial hyperplasia, breast/uterine/ovarian cancer, blood clots (DVT, PE), stroke, heart attack, and dementia (in women 65+). Report unusual vaginal bleeding, chest pain, sudden numbness, or swelling immediately.
• Allergic Reactions: Rare but may include hives, difficulty breathing, or swelling due to tartrazine sensitivity.

Precautions:

• Monitoring: Regular check-ups (every 3–6 months) and monthly breast self-exams are recommended. Annual mammograms are advised due to increased cancer risks.
• Drug Interactions: Estradiol may interact with medications like tucatinib, clarithromycin, cyclosporine, or St. John’s Wort, affecting its metabolism or efficacy. Inform your healthcare provider of all medications and supplements.
• Medical Conditions: Use with caution in patients with asthma, diabetes, epilepsy, migraines, or endometriosis, as estrogens may exacerbate these conditions.
• Surgery/Immobility: Discontinue 4–6 weeks before surgeries with high blood clot risk or during prolonged immobility.

Pharmacokinetics:

• Absorption: Oral estradiol undergoes significant first-pass metabolism in the gastrointestinal tract, resulting in 2–10% bioavailability.
• Metabolism: Metabolized in the liver by cytochrome P450 enzymes into estrone, estriol, and conjugates, excreted in urine.
• Note: Transdermal or vaginal estradiol formulations have higher bioavailability (up to 20 times) due to bypassing first-pass metabolism.

Storage:

• Store at room temperature (68–77°F or 20–25°C), away from moisture and heat. Short-term exposure to 59–86°F (15–30°C) is acceptable (e.g., during transport). Keep out of reach of children.